"This product format will compress product development timelines and create a powerful change in how cell therapies and tissue constructs that require living cells are developed and clinically-translated.” - Jon A. Rowley, PhD, RoosterBio’s CPO
FREDERICK, Md. (PRWEB) December 20, 2018
Today, RoosterBio Inc. announces the launch of RoosterRTP™-XF, a cell vial that’s ready-to-print and ready-to-seed, getting researchers to product development instantly – saving weeks of culture time. This latest product addition, to accelerate clinical translation, is a high-volume hMSC vial and a product line extension of the first generation Ready-to-Print (RTP) product. Now available in a xeno-free formulated (XFF) format, the cells and formulation are free from xeno-containing components and exhibit a more streamlined regulatory profile.
The 50 million viable cell vial has been designed for thaw-and-use applications where researchers directly seed into tissue engineering applications without lengthy cell culture operations. Comprised of cryopreserved human bone marrow-derived hMSCs, this product supports RoosterBio’s development grade (RUO) product portfolio as a fully-expanded cell population. It’s now possible to quickly prototype tissue designs, plug-and-play with bioinks, and/or seed directly into tissue engineering scaffolds removing weeks of pre-work to every experimental cycle, therefore accelerating data collection and overall development timelines.
The product is designed to specifically address the product development bottlenecks of the rapidly evolving Regenerative Medicine (RM) market. A market sub-segment, 3D bioprinting, has experienced notable global growth and is expected to reach $3B by 2025 with roughly a quarter of that total residing in the stem cell space.
“The Tissue Engineering marketplace has benefited from readily available and inexpensive bioprinters, as well as pre-formulated hydrogel bioinks. Our RoosterRTP line of products are the first “cellular bioink” products for rapid tissue bioprinting. This product format, along with companion industry products, will compress product development timelines and create a powerful change in how cell therapies and tissue constructs that require living cells are developed and clinically-translated.” said Jon A. Rowley, PhD, RoosterBio’s CPO. “We’re laying the foundation for simple implementation of hMSCs, meanwhile providing a transparent and streamlined path to cGMP manufactured MSCs for customer-specific applications.”
About RoosterBio Inc.:
RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio’s products are high volume, affordable, and well-characterized adult hMSCs paired with highly engineered bioprocess media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read the blog “Democratizing Cell Technologies” (http://www.roosterbio.blogspot.com).